Journal of the Egyptian National Cancer Institute, published by SPRINGER, serves as a vital platform for disseminating innovative research in the field of oncology and cancer research. With both ISSN 1110-0362 and E-ISSN 2589-0409, this Open Access journal has been committed to making significant contributions to the scientific community since its inception in 2005. Operating from its base in Egypt, it has established itself as an important resource for researchers, practitioners, and students alike, offering insights into contemporary issues and advancements in cancer care. Recognized in the 2023 category quartiles as Q3 in Cancer Research and Q3 in Oncology, the journal is positioned to impact the ongoing discourse in cancer treatment strategies and health policy. As it continues to publish peer-reviewed articles through available Open Access avenues, the Journal of the Egyptian National Cancer Institute remains dedicated to enhancing the knowledge base and collaborative efforts within the global cancer research community.

MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

Cancer and Metastasis Reviews, published by Springer, is a leading journal in the field of oncology and cancer research. With an impressive impact factor placing it in the Q1 category for both Cancer Research and Oncology as of 2023, this journal is ranked 29th out of 404 in Medicine, Oncology, and 22nd out of 230 in Biochemistry, Genetics, and Molecular Biology, reflecting its significant influence and prestige in the academic community. Established in 1982, the journal covers a wide spectrum of topics related to the mechanisms of cancer progression and metastasis, making it an essential resource for researchers, healthcare professionals, and students dedicated to understanding and tackling cancer. Although the journal does not provide open access options, the impactful research it publishes contributes to advances in therapeutic strategies and enhances the collective knowledge surrounding cancer pathophysiology. With research converging from 1982 to 2024, Cancer and Metastasis Reviews continues to be a vital platform for disseminating high-quality scientific information in the ever-evolving landscape of cancer research.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

CURRENT PROBLEMS IN CANCER is an esteemed journal published by MOSBY-ELSEVIER, dedicated to advancing the field of oncology and cancer research. With an ISSN of 0147-0272 and an E-ISSN of 1535-6345, it has been a vital resource for over four decades, converging years of expertise from 1976 to 2024. The journal is recognized for its impactful contribution to the field, currently holding a Q3 ranking in Cancer Research and a Q2 ranking in Oncology, reflecting its importance in disseminating significant advancements and discussions in the field. It is ranked #164 out of 404 in Medicine _ Oncology and #131 out of 230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research on Scopus, indicating its relevance and reach among academic circles. Although it does not offer open access, the journal remains a crucial platform for researchers and professionals seeking to explore contemporary issues in cancer treatment and management. With its commitment to quality and innovation, CURRENT PROBLEMS IN CANCER serves as an essential conduit for knowledge sharing and research development in oncology and cancer science.

BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.